Illustration: Gabriella Turrisi/Axios
Indianapolis pharma giant Eli Lilly plans to buy Ventyx Biosciences for $1.2 billion, the companies said Wednesday.
Why it matters: It's the second pharma M&A deal this week following Amgen's $840 million takeover of Dark Blue Therapeutics.
